+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID04621435

Study of FAP-2286 Imaging to Detect and Evaluate Solid Tumors and Metastatic Cancer Using Gallium-68 and Copper-64 Tracers

Led by Thomas Hope · Updated on 2026-06-04

191

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new imaging method using radiolabeled agents called FAP-2286 to detect metastatic cancer in adults with solid tumors. FAP-2286 binds to a protein found on cancer-associated fibroblasts, present in various solid tumors such as breast, pancreas, sarcoma, prostate, bladder, colon, and head and neck cancers. This phase 1, multi-arm trial aims to assess the safety, dosimetry, uptake, and ability of FAP-2286 to detect metastatic disease and tumor uptake in these cancers. Participants receive either gallium-68 labeled 68Ga- or copper-64 labeled 64Cu- FAP-2286 injected intravenously before undergoing PET imaging. Imaging times vary by cohort and tracer type, ranging from 30 minutes to 24 hours after injection. Some participants may receive contrast during scans if clinically indicated. The study includes cohorts with and without metastatic disease and involves repeated imaging after treatment to evaluate changes in uptake. During the study, participants undergo PET scans lasting about 30 to 45 minutes at scheduled intervals depending on the tracer and disease status. Researchers monitor for treatment-emergent adverse events and measure radiation doses, tracer uptake, tumor-to-background ratios, and lesion detection rates. Participants are followed through the day of their last injection to evaluate safety. The total participation duration depends on individual imaging schedules and treatment plans.

CONDITIONS

Brief Title

Imaging of Solid Tumors Using FAP-2286

Research Team

M

Maya Aslam

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here